T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
FRP Holdings
FRPH
$424M
| $15.2M | ﹤0.01% |
543,902
-48,696
| -8% | -$1.2M |
|
1252
Zai Lab
ZLAB
$2.92B
| $15M | ﹤0.01% |
431,333
+201
| +0% | +$5.92K |
|
|
ESTE
1253
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $15M | ﹤0.01% |
2,456,255
+6,000
| +0.2% | +$39.3K |
|
|
SFLY
1254
DELISTED
Shutterfly, Inc.
SFLY
| $15M | ﹤0.01% |
296,444
-6,417
| -2% | -$293K |
|
|
MCRN
1255
DELISTED
Milacron Holdings Corp.
MCRN
| $14.9M | ﹤0.01% |
1,081,741
+313,276
| +41% | +$4.18M |
|
1256
Axsome Therapeutics
AXSM
$11.2B
| $14.9M | ﹤0.01% |
+578,859
| New | +$11.6M |
|
1257
Duluth Holdings
DLTH
$152M
| $14.7M | ﹤0.01% |
1,083,879
+5,957
| +0.6% | +$96.4K |
|
1258
W.P. Carey
WPC
$16.3B
| $14.7M | ﹤0.01% |
184,324
+111,143
| +152% | +$8.8M |
|
|
SMAR
1259
DELISTED
Smartsheet Inc.
SMAR
| $14.4M | ﹤0.01% |
297,499
-634,274
| -68% | -$26.9M |
|
1260
Albemarle
ALB
$15.4B
| $14.4M | ﹤0.01% |
203,942
+708
| +0.3% | +$52.3K |
|
|
XEC
1261
DELISTED
CIMAREX ENERGY CO
XEC
| $14.3M | ﹤0.01% |
241,384
+2,735
| +1% | +$175K |
|
1262
Federal Signal
FSS
$7.56B
| $14.2M | ﹤0.01% |
529,306
+3,833
| +0.7% | +$101K |
|
1263
New Fortress Energy
NFE
$93.5M
| $14.1M | ﹤0.01% |
1,200,279
+3,384
| +0.3% | +$39K |
|
1264
Healthcare Services Group
HCSG
$1.45B
| $14M | ﹤0.01% |
462,517
-91,932
| -17% | -$3.04M |
|
1265
Xerox
XRX
$411M
| $14M | ﹤0.01% |
395,809
+10,169
| +3% | +$340K |
|
1266
FS Bancorp
FSBW
$324M
| $13.7M | ﹤0.01% |
526,322
+53,500
| +11% | +$1.34M |
|
1267
iShares MSCI India ETF
INDA
$6.59B
| $13.4M | ﹤0.01% |
378,700
| – | – |
|
1268
Kimbell Royalty Partners
KRP
$1.52B
| $13.3M | ﹤0.01% |
+825,571
| New | +$14.1M |
|
1269
Rigel Pharmaceuticals
RIGL
$762M
| $13.3M | ﹤0.01% |
509,623
+40
| +0% | +$903 |
|
|
TECX
1270
Tectonic Therapeutic
TECX
$672M
| $13.1M | ﹤0.01% |
67,353
+16,957
| +34% | +$3.66M |
|
1271
Unum
UNM
$14.7B
| $12.9M | ﹤0.01% |
385,606
-14,719
| -4% | -$510K |
|
1272
CryoPort
CYRX
$770M
| $12.8M | ﹤0.01% |
+700,334
| New | +$11.1M |
|
|
TUES
1273
DELISTED
Tuesday Morning Corp
TUES
| $12.8M | ﹤0.01% |
7,549,535
+32,600
| +0.4% | +$59.3K |
|
1274
Erie Indemnity
ERIE
$13.5B
| $12.7M | ﹤0.01% |
49,788
-7,998
| -14% | -$1.65M |
|
1275
Ironwood Pharmaceuticals
IRWD
$674M
| $12.6M | ﹤0.01% |
1,154,044
-1,475,001
| -56% | -$16.5M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.